Clinical Trials Logo

Penetrating Keratoplasty clinical trials

View clinical trials related to Penetrating Keratoplasty.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00463723 Terminated - Clinical trials for Penetrating Keratoplasty

Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty

Start date: n/a
Phase: Phase 2/Phase 3
Study type: Interventional

Background: Patients following allogeneic keratoplasty are treated with topical and frequently with systemic steroids to prevent immune reactions. Steroids are known to yield good results, but exert a wide range of side effects. The efficacy of topial FK506 in preventing immune reactions has already been demonstrated experimentally. FK506, an IL-2-inhibitor like Cyclosporin A (CSA), is known to be approximately 100 fold more potent than CSA. Aim of the study: In this study the efficacy and safety of topical FK506 will be compared to our standard treatment (i.e. steroids) after penetrating normal-risk keratoplasty.